Bronchial artery embolization is a treatment for hemoptysis, abbreviated as BAE. It is a kind of catheter intervention to control hemoptysis (airway bleeding) by embolizing the bronchial artery, which is a bleeding source. Embolic agents are particulate embolic material such as gelatin sponge or polyvinyl alcohol (PVA), and liquid embolic material such as NBCA, or metallic coils.

Basic principle

It is said that hemoptysis is caused by the formation of anomalous anastomosis (bronchial artery-pulmonary artery shunt) between the bronchial artery and the pulmonary artery, and if the bronchial artery is embolized, hemorrhage will cease. This is a fundamental concept of BAE. Traditionally, BAE was mostly performed as an emergency hemostatic procedure. Recently, it is often performed as an elective catheter treatment to prevent recurrence after massive hemoptysis, or control chronic repetitive hemoptysis. Although it is termed bronchial artery embolization, various systemic arteries other than the bronchial artery (non-bronchial arteries) also form a shunt with the pulmonary artery and cause hemoptysis. Therefore, it is common to embolize such non-bronchial arteries, but the expression of bronchial artery embolization, BAE, rather than the universal expression "arterial embolization" is more common. The therapeutic outcomes are improving due to the combined approach such as spreading the treatment target to non-bronchial arteries, development of 3D-CT angiography following the development of MDCT, the advancement of devices such as coils and micro-catheters, and the evolution of therapeutic strategies. BAE has become the gold standard for hemoptysis for its dramatic improvement. Although the hemostatic effect is greatly affected by the underlying disease, some high-volume centers report hemostatic rate of about 90.4% within one year of treatment, and 85.9% even in two years after treatment. The occlusion of the blood vessels in the brain, heart, and kidneys, which are supplied by the so-called end arteries, can cause cerebral, myocardial, and renal infarctions. In BAE, both bronchial mucosal necrosis and pulmonary infarction seldom occur. It is presumed that this is because the pulmonary circulation is dually controlled by the bronchial artery and the pulmonary artery; and even if the blood flow in the bronchial artery is lost, blood flow from the pulmonary artery is slightly maintained. In the case of non-bronchial arteries, it is empirically known that some collateral circulations also develop. In addition, direct hemorrhage from the pulmonary artery is rare (less than 5%), which requires embolization of the pulmonary artery.

Bronchial artery embolization

Treatment indications

BAE is effective for hemoptysis in most underlying diseases such as bronchiectasis, nontuberculous mycobacterial disease (NTM), cryptogenic hemoptysis, pulmonary aspergillosis, and pulmonary tuberculosis sequelae. According to Ishikawa who reported long-term treatment results of BAE for 489 hemoptysis patients, each underlying disease's ratio is 34.0%, 23.5%, 18.4%, 13.3%, 6.8%, respectively. Other diseases for which BAE is effective include lung abscess and pulmonary actinomycosis.

Bronchial artery embolization

As for lung cancer, hemoptysis is caused mostly by bleeding from the tumor itself, and not by the bronchial-pulmonary artery shunt mechanism; embolism of the feeding vessels for the tumor causes necrosis of the cancer which may evoke massive hemoptysis. In addition, subsequent chemotherapy and endovascular treatment cannot be performed if the route of anticancer drugs is permanently obstructed. Lung cancer needs a different strategy. Seki et al. reported the usefulness of endovascular treatment for lung cancer hemoptysis. Kichang et al. reported BAE for hemoptysis in 84 lung cancer patients, and demonstrated that massive hemoptysis and cavity formation were significantly poor prognosis factors; re-hemoptysis rate was 23.8% in their follow-up period.

Bronchial artery embolization

Even though BAE is currently considered the gold standard treatment for hemoptysis, Ishikawa et al. found that only 9065 patients (8.4%) out of 107389 patients hospitalized for hemoptysis between 2010 and 2018 in Japan were treated with BAE. According to Ishikawa basically, all patients with hemoptysis who are admitted to the hospital are eligible for BAE, and the reason why BAE has been performed only in such a small number of patients is that there are still few facilities that can perform BAE,

Besides, among the 660 hospitals that performed BAE, half of them (334 centers) experienced less than one case per year. Centralization of hemoptysis treatment facilities will be necessary to increase the performance rate of BAE and to improve the quality of BAE.